Scientific documents library
Filter results by document type and/or working area to find what you're searching for.
Emicizumab (Hemlibra®, Roche Pharma AG) is a humanised, modified, monoclonal immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure. Emicizumab substitutes part of the cofactor function of activated factor VIII (FVIIIa) by bridging activated factor IX (FIXa) and factor X (FX) to restore effective haemostasis in HA individuals.
Doping with blood, erythropoietin or related substances is an unfair practice in sports and is performed to obtain an advantage over competing athletes. Doping control has made great progress in detecting the use of forbidden substances by employing completely new strategies that no longer rely on the detection of the banned substance itself. What is measured instead are the changes that forbidden doping practice has on haematological parameters.
Chronic kidney disease (CKD) is a severe complication in context of various civilisation diseases, such as diabetes, hypertension, and obesity. With increasing treatment cost along the progression of CKD towards end-stage renal failure (ESRF) and the need for renal replacement therapies, CKD is not only a driver of premature mortality and diminished quality of life of affected individuals, but also puts significant burden on the society and healthcare expenditures. The early detection of kidney damage through a frequent screening of risk patients could help to fight the burden of CKD. Cost-efficient routine urinalysis data could play a vital role in providing valuable information for screening, diagnosing, and monitoring of renal disorders.
Right from the very beginning, flow cytometry was developed for measuring variations in the quantity of genetic material in dysplastic cells. This technology remains the reference method in plant biology for assessing the size of a genome and the level of ploidy.
This clinical information card presents how the XN-DIFF and the WPC channel, by using their unique reagent systems, allow conclusion on cell maturity, activation status of a cell, and cell malignancies using different examples.
This clinical infromation card explains functional iron deficiency (FID) and the advantages of the parameter RET-He (reticulocyte haemoglobin equivalent) as it reflects the the iron availability for haemoglobination in the bone marrow in real-time. A patient case illustrates how RET-He helps to monitor the iron availability at diagnosis and during treatment of FID.
The lab information card is illustrating the value of the WPC channel and the Extended Inflammation Parameters. The front side addresses the lab and clinical benefits, the flip side contains technical information.